CSPC Pharmaceutical Group Limited (1093.HK)

CSPC Pharmaceutical’s adjusted EPS of CNY 0.62 topped the CNY 0.16 estimate, +277%, as revenue rose 40.9% to about CNY 18.3 billion in the first half of fiscal 2026, reported on August 20. Net income climbed 140.5% to roughly CNY 6.0 billion from about CNY 2.5 billion a year ago, while adjusted EPS improved from CNY 0.12. Gross margin was near 76% and operating margin around 40%, with operating income at about CNY 7.2 billion. Operating cash flow came in at about CNY 2.8 billion, and the company paid about CNY 2.5 billion in dividends. Consensus for the next period calls for EPS of CNY 0.28.